NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

This study is testing a chemotherapy-plus-immunotherapy combination that avoids the use of anthracyclines (a class of chemotherapy drugs that can damage the heart) in people with triple-negative breast cancer (TNBC), a fast-growing type of breast cancer that lacks the three most common hormone receptors. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of Stage II or IIIA/B triple-negative breast cancer - Your tumor is larger than 1 cm (with or without spread to lymph nodes) - You are otherwise healthy enough for cancer surgery - You have a cardiologist or primary care doctor available to monitor your heart health **You may NOT be eligible if...** - You have inflammatory breast cancer - You have prior chemotherapy or radiation for this cancer - You have significant heart disease that can't be managed - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.